Sign In
Buy IRON
$70.35
+2.35 (+3.46%)
At Close: Jun 03, 2026
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
08:30am, Thursday, 19'th Sep 2024
Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs Dr. Steve Caffé is an accomplished industry executive with
Disc Medicine to Participate in Upcoming Investor Conferences
08:00am, Friday, 30'th Aug 2024
WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
LEADING FINTECH MONEYTHUMB ACQUIRED BY IRON CREEK
07:01am, Thursday, 29'th Aug 2024
Partnership to Accelerate Future Growth and Innovation of MoneyThumb's SaaS Document Evaluation Technology SAN DIEGO , Aug. 29, 2024 /PRNewswire/ -- MoneyThumb, a leader in automated document evaluat
Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress
01:26pm, Friday, 14'th Jun 2024
Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using b
Disc Medicine Announces Underwritten Offering of Common Stock
08:03am, Friday, 14'th Jun 2024
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
07:30am, Friday, 14'th Jun 2024
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
09:00am, Thursday, 30'th May 2024
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
10:30am, Tuesday, 14'th May 2024
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
08:00am, Monday, 13'th May 2024
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
08:00am, Thursday, 09'th May 2024
WATERTOWN, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
03:26pm, Tuesday, 02'nd Apr 2024
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)
08:01am, Tuesday, 02'nd Apr 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Disc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity Study
09:06am, Monday, 01'st Apr 2024
Disc's light sensitivity drug succeeded in a test Monday, but a large placebo response confounded the results. The biotech stock plummeted.
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
08:00am, Monday, 01'st Apr 2024
WATERTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
08:00am, Thursday, 21'st Mar 2024
WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
